{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:19:36Z","timestamp":1769048376761,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior Reports"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ebr.2022.100574","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T10:07:22Z","timestamp":1668420442000},"page":"100574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Effectiveness and tolerability of lacosamide in children with drug resistant epilepsy"],"prefix":"10.1016","volume":"21","author":[{"given":"J.T.","family":"Driessen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.A.","family":"Wammes\u2013van der Heijden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Verschuure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.C.F.M.","family":"Fasen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.W.A.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.J.M.","family":"Majoie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ebr.2022.100574_b0005","doi-asserted-by":"crossref","DOI":"10.1002\/ana.20852","article-title":"How long does it take for epilepsy to become intractable? A prospective investigation","volume":"60","author":"Berg","year":"2006","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.ebr.2022.100574_b0010","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1533-2500.2004.04304.x","article-title":"Side Effects of Antiepileptics\u2014 A Review","volume":"4","author":"Walia","year":"2004","journal-title":"Pain Practice"},{"key":"10.1016\/j.ebr.2022.100574_b0015","unstructured":"UBC. Vimpat. Published 2017. Accessed November 10, 2021. https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-s-anti-epileptic-drug-VIMPAT-lacosamide-receives-EU-approval-for-paediatric-use."},{"key":"10.1016\/j.ebr.2022.100574_b0020","unstructured":"Vimpat | European Medicines Agency. Accessed May 2, 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vimpat."},{"key":"10.1016\/j.ebr.2022.100574_b0025","unstructured":"CHMP. Vimpat, INN-lacosamide. Accessed January 22, 2022. www.ema.europa.eu\/contact."},{"key":"10.1016\/j.ebr.2022.100574_b0030","series-title":"Basic & Clinical Pharmacology","author":"Katzung","year":"2014"},{"issue":"7","key":"10.1016\/j.ebr.2022.100574_b0035","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1528-1157.1998.tb01167.x","article-title":"Considerations on Designing Clinical Trials to Evaluate the Place of New Antiepileptic Drugs in the Treatment of Newly Diagnosed and Chronic Patients with Epilepsy","volume":"39","author":"Chadwick","year":"1998","journal-title":"Epilepsia"},{"issue":"1\u20132","key":"10.1016\/j.ebr.2022.100574_b0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yebeh.2010.04.001","article-title":"Measuring outcomes of treatment with antiepileptic drugs in clinical trials","volume":"18","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.ebr.2022.100574_b0045","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/epi.13671","article-title":"Instruction manual for the ILAE 2017 operational classification of seizure types","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2022.100574_b0050","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.yebeh.2017.11.024","article-title":"The effectiveness and safety of lacosamide in children with epilepsy in a clinical practice setting","volume":"79","author":"Sanmart\u00ed-Vilaplana","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.ebr.2022.100574_b0055","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/jpc.14156","article-title":"Lacosamide in children with drug-resistant epilepsy","volume":"55","author":"R\u00fcegger","year":"2019","journal-title":"J Paediatr Child Health"},{"issue":"9","key":"10.1016\/j.ebr.2022.100574_b0060","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/epi.13466","article-title":"Lacosamide use in children with epilepsy: Retention rate and effect of concomitant sodium channel blockers in a large cohort","volume":"57","author":"McGinnis","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2022.100574_b0065","doi-asserted-by":"crossref","unstructured":"Rosati A, Lucrezia Ilvento |, Rizzi R, et al. Long-term efficacy of add-on lacosamide treatment in children and adolescents with refractory epilepsies: A single-center observational study. Published online 2018. 10.1111\/epi.14071.","DOI":"10.1111\/epi.14071"},{"key":"10.1016\/j.ebr.2022.100574_b0070","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.yebeh.2019.03.003","article-title":"Brief Communication Evolving dynamic networks: An underlying mechanism of drug resistance in epilepsy?","volume":"94","author":"Woldman","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2022.100574_b0075","unstructured":"Tolerance and the Honeymoon Effect | Epilepsy Foundation. Accessed May 14, 2022. https:\/\/www.epilepsy.com\/stories\/tolerance-and-honeymoon-effect."},{"issue":"11","key":"10.1016\/j.ebr.2022.100574_b0080","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/adc.2005.080002","article-title":"Alternative approaches to conventional antiepileptic drugs in the management of paediatric epilepsy","volume":"91","author":"Kneen","year":"2006","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.ebr.2022.100574_b0085","unstructured":"Drug-Resistant Epilepsy | Epilepsy Foundation. Accessed January 26, 2022. https:\/\/www.epilepsy.com\/learn\/drug-resistant-epilepsy."},{"issue":"11","key":"10.1016\/j.ebr.2022.100574_b0090","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s13312-013-0284-9","article-title":"Newer anti-epileptic drugs","volume":"50","author":"Aneja","year":"2013","journal-title":"Indian Pediatr"},{"issue":"4","key":"10.1016\/j.ebr.2022.100574_b0095","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.pediatrneurol.2014.07.004","article-title":"Efficacy and tolerability of lacosamide as an adjunctive therapy in children with refractory partial epilepsy","volume":"51","author":"Pasha","year":"2014","journal-title":"Pediatr Neurol"},{"issue":"3","key":"10.1016\/j.ebr.2022.100574_b0100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.ebr.2022.100574_b0105","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.ebr.2022.100574_b0110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yebeh.2010.10.002","article-title":"Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction?","volume":"20","author":"Novy","year":"2011","journal-title":"Epilepsy Behav"},{"issue":"Pt A","key":"10.1016\/j.ebr.2022.100574_b0115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.yebeh.2016.02.007","article-title":"Lacosamide tolerability in adult patients with partial-onset seizures: Impact of planned reduction and mechanism of action of concomitant antiepileptic drugs","volume":"57","author":"Foldvary-Schaefer","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.ebr.2022.100574_b0120","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2011.11.026","article-title":"Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA","volume":"23","author":"Villanueva","year":"2012","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.ebr.2022.100574_b0125","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s13760-019-01098-3","article-title":"Lacosamide in patients with intellectual disability and refractory epilepsy","volume":"119","author":"Kleist","year":"2019","journal-title":"Acta Neurol Belg"}],"container-title":["Epilepsy & Behavior Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258998642200051X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258998642200051X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:08:02Z","timestamp":1762906082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258998642200051X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":25,"alternative-id":["S258998642200051X"],"URL":"https:\/\/doi.org\/10.1016\/j.ebr.2022.100574","relation":{},"ISSN":["2589-9864"],"issn-type":[{"value":"2589-9864","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and tolerability of lacosamide in children with drug resistant epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebr.2022.100574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100574"}}